Relation of Guideline Adherence to Outcomes in Patients With Asymptomatic Severe Primary Mitral Regurgitation.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
15 09 2021
Historique:
received: 23 09 2020
revised: 12 05 2021
accepted: 17 05 2021
pubmed: 30 7 2021
medline: 22 9 2021
entrez: 29 7 2021
Statut: ppublish

Résumé

Current guidelines empirically recommend serial clinical evaluations for asymptomatic patients with severe mitral regurgitation (MR). However, there is a paucity of data on the effectiveness of such monitoring. This study sought to examine the potential benefit of guideline adherence among asymptomatic patients with severe primary MR. Asymptomatic patients with severe primary MR who had been evaluated in the Allina Health system between January 1, 2012 and May 30, 2018 were examined. The medical records were manually reviewed for demographics, comorbidities, echocardiographic data, subsequent interventions, and clinical outcomes. Patients were grouped according to occurrence of guideline adherence, which was defined as a serial clinical evaluation with echocardiography every 12 ± 1 month until mitral valve surgery, or death. Over the study period, 246 patients (67.3 ± 15.5 years, 61.4% men) with severe, asymptomatic primary MR were identified, including 154 patients (62.6%) with and 92 patients (37.4%) without guideline adherence. Overall, there were no differences in demographics, morbidities, MR severity, or left ventricular function between patient adherence groups. During follow-up (40.9; 21.2, 58.3 months), patients with adherence more frequently had surgery or transcatheter therapy performed (64.3% vs 18.5%; p <0.001) and the time to intervention was earlier (13.6 [3.9-22.7] vs 44.2[25.6-57.3] months; p <0.001). Compared to non-adherent patients, those with guideline adherence had a significantly higher five-year survival free from all-cause mortality (92.0% vs 74.3%, p = 0.002), and freedom from death or hospitalization for heart failure (90.1% vs 69.3%, p = 0.001). Adherent patients also had a significantly better survival free from combined endpoint of death, re-hospitalization for heart failure, myocardial infarction, and stroke (84.5% vs 63.2%, p = 0.002). In patients with asymptomatic severe primary MR, guideline adherence with serial evaluations every 12 months or less is associated with earlier therapy and improved long-term outcomes. These data support educational efforts to promote guideline adherence.

Identifiants

pubmed: 34325105
pii: S0002-9149(21)00585-3
doi: 10.1016/j.amjcard.2021.05.054
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

113-120

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosures The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Liang Tang (L)

Valve Science Center, Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minnesota; Department of Cardiology, the Second Xiangya Hospital of Central South University, Changsha, China.

Kevin M Harris (KM)

Valve Science Center, Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minnesota.

Ross Garberich (R)

Valve Science Center, Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minnesota.

Mario Gössl (M)

Valve Science Center, Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minnesota.

Joao L Cavalcante (JL)

Valve Science Center, Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minnesota.

Steven M Bradley (SM)

Valve Science Center, Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minnesota.

Aisha Ahmed (A)

Valve Science Center, Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minnesota.

John R Lesser (JR)

Valve Science Center, Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minnesota.

Richard Bae (R)

Valve Science Center, Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minnesota.

Benjamin Sun (B)

Valve Science Center, Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minnesota.

Karol Mudy (K)

Valve Science Center, Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minnesota.

Paul Sorajja (P)

Valve Science Center, Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minnesota. Electronic address: paul.sorajja@allina.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH